Covinnovations™ recently received some positive and encouraging comments on its funding application to the National Institue of Health (NIH), with emphasis on the validity of the science behind COVID treatment COVI-001, which has demonstrated the potential to directly combat and halt COVID-19 after people have become infected with the disease, particularly those with intense reactions which have been hospitalized and are receiving oxygen. 

This month, Covinnovations™ was awarded a Technical Watch meeting with the Biomedical Advanced Research and Development Authority (BARDA). A Tech Watch meeting is an opportunity for the U.S. government experts to discuss a company’s product or technology and explore potential partnership.  . 

According to the Centers for Disease Control and Prevention (CDC) COVID Tracker, 2,885 Americans died from COVID just last week (9/7/22). While this number is down from the height of the pandemic, that is still 2,800+ families suffering the loss of a loved one on a weekly basis.

A proposed treatment from CovinnovationsTM (COVI-001) comprised of two FDA approved medications has demonstrated the potential to directly combat and halt COVID-19 after people have become infected with the disease, particularly those with intense reactions which have been hospitalized and are receiving oxygen.

Covinnovations™, a Las Vegas-based developer of later-stage COVID-19 treatments, is looking to raise USD 25m, interim CEO Kristine Leavitt told Mergermarket during the Biotech Showcase Conference.

Preliminary data for new late-stage treatment shows at least 93.5 percent survival rate for patients who are oxygen dependent or intubated.

CovInnovations™ revealed today that the company’s Rapid RNA COVID-19 test, CovaTest™, is expected to not only detect the presence of COVID-19, but also identify the strain of the disease if it is present. The Rapid RNA test is in the pre-prototype phase of development. If validated, it will be a new non-invasive way of testing for COVID-19 with a simple saliva sample test. The test will reveal results in just a couple of minutes.

Covinnovations™ announced Friday that it has begun the process for FDA Emergency Use Authorization (EUA) for its CovArrest™ COVID-19 treatment. CovArrest™ is a patent-pending, trademarked drug combination, created by founder and inventor, Dr. Aury Nagy. It halts the cytokine storm that COVID-19 creates. “It is the cytokine storm that, in turn, kills so many people,” Covinnovations™ said in a statement.

Covinnovations™ has been invited to participate in the 2022 Biotech Showcase, an investor conference for innovators in medical, life sciences and other biotechnology industries, January 10-12, 2022.

Key management personnel from CovInnovations™ attended the Institute for Biomedical Entrepreneurship (IBE) conference in Boston, meeting and making connections with leaders of multiple sectors of the bio tech industry. IBE brings specialized know-how and funding to biomedical researchers and innovators with educational programs and hands-on training that will help them become more aware of how to make their discoveries end up in the marketplace.

Throughout the summer, CovInnovations™ made great strides toward bringing its revolutionary COVID-19 treatment, CovArrest™, to market.

CovInnovations™ has secured $480,000 in funding that will be utilized to accelerate the FDA approval process for CovArrest™, the revolutionary new treatment for hospitalized patients with severe COVID-19 symptoms. The company retained Biotech Research Group, a full service regulatory and product development consulting firm, to help guide the FDA-submission process. BRG has an excellent reputation as a leading regulatory and scientific affairs consulting firm, and the company has clients and consultants in more than 60 countries across the globe.